Compare GNT & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNT | CMPX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.6M | 154.9M |
| IPO Year | N/A | 2020 |
| Metric | GNT | CMPX |
|---|---|---|
| Price | $8.42 | $0.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $5.45 |
| AVG Volume (30 Days) | 39.4K | ★ 6.2M |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.94 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.68 | $0.82 |
| 52 Week High | $9.38 | $6.88 |
| Indicator | GNT | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 24.28 |
| Support Level | $8.20 | $0.83 |
| Resistance Level | $8.57 | $2.51 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 41.50 | 8.88 |
GAMCO Natural Resources, Gold & Income Trust is a non-diversified closed-end management investment company. The company's primary investment objective is to provide a high level of current income from interest, dividends, and options premiums with its secondary objective being capital appreciation. Under normal market conditions, the company invests majority of its assets in securities of companies principally engaged in the natural resources and gold industries, and also engages in writing covered call options on the underlying equity securities. Its portfolio consists of securities from different sectors such as metals and mining, energy and energy services, specialty chemicals, agriculture, healthcare, machinery, food and beverage, and others.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.